Nabilone

Generic Name: Nabilone

Brand Names: Cesamet

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₆O_₃

CAS Number: 51022-71-0

Unique Ingredient Identifier: 2N4O9L084N

Background: Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however...

Indication: Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic re...

Associated Conditions: Refractory Chemotherapy-Induced Nausea and Vomiting (CINV)

Associated Therapies: -

Clinical Trials

Nabilone for Agitation in Frontotemporal Dementia

Phase 2

Active, not recruiting

Conditions: Frontotemporal Dementia
FTD
Frontotemporal Dementia, Behavioral Variant
bvFTD
PPA
Primary Progressive Aphasia

Interventions: Drug: Placebo
Drug: Nabilone

First Posted Date: 2023-02-24

Last Posted Date: 2023-10-13

Lead Sponsor: Simon Ducharme, MD

Target Recruit Count: 45

Registration Number: NCT05742698

Locations: 🇨🇦
University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦
Western Hospital - University of Toronto, Toronto, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 4 locations

Effect of PP-01 on Cannabis Withdrawal Syndrome

Phase 2

Completed

Conditions: Cannabis Withdrawal

Interventions: Combination Product: PP-01 High Dose
Combination Product: PP-01 Low Dose
Drug: Placebo
Drug: Nabilone
Drug: Gabapentin

First Posted Date: 2022-08-10

Last Posted Date: 2024-08-16

Lead Sponsor: PleoPharma, Inc.

Target Recruit Count: 234

Registration Number: NCT05494437

Locations: 🇺🇸
Pahl Pharmaceutical Professionals LLC, Oklahoma City, Oklahoma, United States
🇺🇸
Pillar Clinical Research, LLC, Chicago, Illinois, United States
🇺🇸
Behavioral Research Specialists, LLC, Glendale, California, United States

and more 15 locations

Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities

Phase 1

Recruiting

Conditions: Behavior Problem
Intellectual Disability
Developmental Disability
Aggression

Interventions: Drug: Nabilone

First Posted Date: 2022-03-10

Last Posted Date: 2024-01-10

Lead Sponsor: Hsiang-Yuan Lin

Target Recruit Count: 30

Registration Number: NCT05273320

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

Phase 1

Withdrawn

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Placebo
Drug: Nabilone

First Posted Date: 2021-05-10

Last Posted Date: 2024-05-21

Lead Sponsor: New York State Psychiatric Institute

Registration Number: NCT04880278

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Phase 2

Withdrawn

Conditions: Suicidal Ideation

Interventions: Drug: Placebo
Drug: Nabilone

First Posted Date: 2021-03-19

Last Posted Date: 2021-09-22

Lead Sponsor: The University of Texas Health Science Center, Houston

Registration Number: NCT04807829

Locations: 🇺🇸
Harris County Psychiatric Center (HCPC), Houston, Texas, United States

A Pilot Trial of Nabilone for the Treatment of Obesity

Phase 2

Terminated

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Nabilone

First Posted Date: 2021-03-17

Last Posted Date: 2024-01-29

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 24

Registration Number: NCT04801641

Locations: 🇨🇦
Center for Addiction and Mental Health, Toronto, Ontario, Canada

Nabilone for Agitation Blinded Intervention Trial

Phase 3

Recruiting

Conditions: Alzheimer Disease
Agitation

Interventions: Other: Placebo
Drug: Nabilone

First Posted Date: 2020-08-17

Last Posted Date: 2023-07-25

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 112

Registration Number: NCT04516057

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 2 locations

Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients

Not Applicable

Not yet recruiting

Conditions: Inflammatory Bowel Diseases

Interventions: Drug: Placebos
Drug: Nabilone

First Posted Date: 2018-02-06

Last Posted Date: 2023-06-07

Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Target Recruit Count: 80

Registration Number: NCT03422861

Locations: 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

Nabilone in Cannabis Users With PTSD

Phase 1

Terminated

Conditions: Cannabis
Post Traumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Nabilone
Drug: Propranolol
Drug: Cannabis

First Posted Date: 2017-08-16

Last Posted Date: 2022-07-15

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 4

Registration Number: NCT03251326

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

Completed

Conditions: FBSS

Interventions: Drug: Nabilone
Drug: THC/CBD

First Posted Date: 2017-07-07

Last Posted Date: 2019-01-16

Lead Sponsor: Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Target Recruit Count: 20

Registration Number: NCT03210766

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy